Relapse of Escherichia coli meningitis following therapy with moxalactam.

Abstract

Bacteriologic relapse occurred in a premature infant with Escherichia coli K1 meningitis 11 days following the completion of a 3-week course of therapy with the new 1-oxa-beta-lactam antibiotic moxalactam. Therapeutic failure was most probably the result of sequestration of viable bacteria in ventricular and/or paraventricular sites. While in vitro data and preliminary clinical evaluation of the new beta-lactam antibiotics indicate that these agents may be useful in the treatment of neonatal Gram-negative enteric meningitis, undue optimism regarding their efficacy, as with former agents, may be unwarranted.

• Authors: R A Broughton, E O Mason, C J Baker
• Journal: Pediatric infectious disease (Pediatr Infect Dis) 1982 Jan-Feb Vol. 1 Issue 1 Pg. 24-8 ISSN: 0277-9730 [Print] United States
• PMID: 6217454 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Cephalosporins
• Cephamycins
• Moxalactam

Topics

• Cephalosporins (therapeutic use)
• Cephamycins (therapeutic use)
• Escherichia coli Infections (drug therapy)
• Humans
• Infant, Newborn
• Infant, Newborn, Diseases (drug therapy)
• Male
• Meningitis (drug therapy)
• Moxalactam
• Recurrence